Pneumonia and other serious adverse events · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with pulmonary hypertension
Exercise showed no clear difference in serious adverse events compared with control (moderate certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Umeclidinium bromide showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause serious adverse events · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium leads to lower all‐cause serious adverse events compared with ipratropium (high certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with stable chronic obstructive pulmonary disease
It is very uncertain whether aclidinium bromide changes non‐fatal serious adverse events compared with tiotropium (very low certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Tiotropium + LABA/ICS combination showed no clear difference in serious adverse events (non‐fatal) compared with tiotropium (low certainty).
1 finding from 1 review
Serious adverse events Adverse events · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in serious adverse events Adverse events compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
1 finding from 1 review
Intervention not reported
Non‐fatal, serious adverse events (all) · patients with chronic obstructive pulmonary disease
The intervention showed no clear difference in non‐fatal, serious adverse events (all) (moderate certainty).
1 finding from 1 review
Intervention not reported
Non‐fatal, serious adverse events (all) · patients with chronic obstructive pulmonary disease
The intervention showed no clear difference in non‐fatal, serious adverse events (all) (high certainty).
1 finding from 1 review
Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Adverse events (not including serious adverse events): number of participants · patients with chronic obstructive pulmonary disease
Umeclidinium bromide showed no clear difference in adverse events (not including serious adverse events) compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events—serious—400/103 Duration of six months · patients with chronic obstructive pulmonary disease
Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—400/103 Duration of six months compared with placebo (low certainty).
1 finding from 1 review
OR 1.09 [0.66, 1.79]
890 participants
Low
Adverse events—serious—200/103 Duration of six months · patients with chronic obstructive pulmonary disease
Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—200/103 Duration of six months compared with placebo (low certainty).
1 finding from 1 review
OR 0.71 [0.41, 1.23]
894 participants
Low
All‐cause serious adverse events 60 weeks (end of study) · patients with chronic obstructive pulmonary disease
It is very uncertain whether macrolide+tetracycline changes all‐cause serious adverse events 60 weeks (end of study) compared with macrolide (very low certainty).
1 finding from 1 review
Intervention not reported
Serious Adverse Events (Participants with one or more event) · Adults (>18 years) with pulmonary hypertension of varied aetiology (PAH, CTEPH and left heart disease)
It is very uncertain whether the intervention changes serious Adverse Events (Participants with one or more event) (very low certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · the management of chronic obstructive pulmonary disease
Multi‐component intervention showed no clear difference in adverse events: number of people experiencing a serious adverse event compared with other intervention or routine, usual care or control treatment (low certainty).
1 finding from 1 review